The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Personalized circulating tumor DNA (ctDNA) analysis in patients with recurrent/metastatic head and neck squamous cell cancer (R/M HNSCC).
 
Kirsty Taylor
No Relationships to Disclose
 
Jinfeng Zou
No Relationships to Disclose
 
Marcos Aurelio Fonseca Magalhaes Filho
No Relationships to Disclose
 
Karen Howarth
Employment - Inivata
Stock and Other Ownership Interests - Inivata; NeoGenomics Laboratories
Research Funding - Inivata
Patents, Royalties, Other Intellectual Property - Patent pending
 
Giovanni Marsico
Employment - Inivata
 
Samantha Terrell
Employment - Inivata
 
Gregory Jones
Employment - INIVATA
Patents, Royalties, Other Intellectual Property - Patent for plasma cfDNA sequencing and prediction of I/O therapy response (Inst)
 
Charlene Knape
Employment - INIVATA
 
Tim Forshew
Employment - Inivata
 
Marc Oliva
Honoraria - Merck; MSD Oncology; Transgene
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - Merck
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Pfizer; Merck; MSD Oncology
Other Relationship - Bristol-Myers Squibb; Merck; MSD Oncology
 
Anna Spreafico
Honoraria - Bristol-Myers Squibb; Medison & Immunocore
Consulting or Advisory Role - Bristol-Myers Squibb; Medison & Immunocore; Merck; Novartis; Oncorus
Research Funding - Alkermes; Amgen (Inst); Array BioPharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; GlaxoSmithKline; Janssen Oncology; Merck; Northern Biologics; Novartis; Replimune; Roche; Surface Oncology; Symphogen; Treadwell Therapeutics (Inst)
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Idera; Janssen Oncology; Merck; Roche
 
Aaron Richard Hansen
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Eisai; GlaxoSmithKline; Merck; Novartis
Research Funding - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Boehringer Ingelheim; Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Neoleukin Therapeutics (Inst); Pfizer/EMD Serono (Inst); Roche/Genentech (Inst)
 
Simon McDade
Stock and Other Ownership Interests - AilseVax
Patents, Royalties, Other Intellectual Property - AilseVax
 
Victoria M. Coyle
Honoraria - Gilead Sciences (I); SERVIER
Consulting or Advisory Role - SERVIER
Research Funding - Astex Pharmaceuticals (Inst); Bayer (Inst); CellCentric (Inst)
Travel, Accommodations, Expenses - SERVIER
 
Mark Lawler
Honoraria - Bayer; Carnall Farrar; EMD Serono/Merck; Novartis; Pfizer; Roche
Research Funding - Pfizer (Inst)
 
Elena Elimova
Employment - Merck (I)
Consulting or Advisory Role - Adaptimmune (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Zymeworks (Inst)
Research Funding - AstraZeneca Canada (Inst); Bristol-Myers Squibb; Zymeworks
 
Scott Victor Bratman
Employment - Adela
Leadership - Adela
Stock and Other Ownership Interests - Adela
Research Funding - Nektar
Patents, Royalties, Other Intellectual Property - Co-inventor and holder of a patent related to circulating tumor DNA detection technology.; Co-inventor of patents related to cell-free DNA methylation analysis technology. (Inst)
 
Lillian L. Siu
Leadership - Treadwell Therapeutics (I)
Stock and Other Ownership Interests - Agios (I)
Consulting or Advisory Role - Amgen; Arvinas; AstraZeneca/MedImmune; Daiichi Sankyo/UCB Japan; GlaxoSmithKline; Hookipa Pharma; InterRNA; Janpix; Janssen; Merck; Navire; Oncorus; Relay Therapeutics; Roche; Sanofi; Seagen; Tessa Therapeutics; Voronoi Health Analytics
Research Funding - Amgen (Inst); Amgen (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVID Radiopharmaceuticals (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Intensity Therapeutics (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Shattuck Labs (Inst); Symphogen (Inst)